Good
Mostly Aligned
Patient Risk:
Low
Summary
The AI evaluation largely aligns with the label: core indications, dosage formats, dosing ranges, and key adverse effects are correctly identified. Several statements are not explicitly supported by the label (notably generic/brand naming and explicit statement that dosing/duration depend on individual condition), and some claims are only partially supported (e.g., broader statements about 'other measures' beyond rest/PT as encompassed by the label). There are notable omissions (Rx-only status, contraindications detail, explicit pregnancy/pediatrics guidance) that affect safety/safe-use considerations.
Category Scores
Accurate Statements
Indication cites relief of discomfort associated with acute, painful musculoskeletal conditions.
INDICATIONS AND USAGE
Common adverse effects include dizziness, drowsiness, headache, and nausea.
ADVERSE REACTIONS
There are serious adverse events listed (e.g., anaphylactic reactions, seizures) and warnings about potential serious effects.
ADVERSE REACTIONS, WARNINGS
Dosage and administration sections provide 500 mg and 750 mg strengths with initial and maintenance dosing, and specify high daily totals in the first 48–72 hours.
DOSAGE AND ADMINISTRATION
First 48–72 hours may involve up to six grams per day; for severe conditions up to eight grams per day may be administered; thereafter reduction is possible.
DOSAGE AND ADMINISTRATION
Indication describes adjunct to rest, physical therapy, and other measures for relief of discomfort.
INDICATIONS AND USAGE
Unsupported Statements
Methocarbamol is available in generic forms.
No section of the provided label discusses generic forms.
Methocarbamol is available under the brand name Robaxin.
No section of the label mentions Robaxin or any brand name.
Dosages depend on the individual's condition and response to the medication.
The label provides specific initial/maintenance dosing regimens rather than an explicit statement that dosing depends on individual condition/response.
Pricing information varies by dosage and brand/generic status.
Pricing is not discussed in the label sections provided.
Insurance coverage/out-of-pocket costs influence use.
Insurance/cost discussions are not in the label sections provided.
Methocarbamol is prescription-only.
The label excerpt does not explicitly state Rx-only; typical labeling may include Rx-only, but this is not shown in the provided sections.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
Rx-only status clearly stated on-label
Importance:
High
Contraindications details
Importance:
High
Pregnancy/pregnancy risk information (pregnancy category, fetal safety)
Importance:
High
Pediatric safety/dosing information
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Label lists multiple adverse reactions and warnings, including CNS depressant effects and pregnancy cautions; overall safety considerations rely on standard dosing and monitoring.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Some statements extend beyond explicit label content (e.g., brand/generic naming, explicit Rx-only status, and cost-related considerations) and several important safety details are omitted.
Suggested Improvement
Refine claims to align strictly with label language; add explicit Rx-only status, contraindications, pregnancy/pediatrics guidance, and cost/insurance considerations only if provided by the label or official labeling supplements.